ArticleOpen forum infectious diseases2025
Measles Population Immunity in Hunan, China: A Serological Assessment.
Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Sustained suppression of measles in China despite a global resurgence: drivers, risks, and strategic preparedness.World journal of pediatrics : WJP · 2026Article
- Seroprevalence of measles immunoglobulin G antibodies in Bahrain: A cross-sectional study using fever and rash surveillance data (2021-2025).IJID regions · 2026Article
- COVID-19 pandemic and waning immunity disrupted measles population immunity and strategies to close immunity gaps.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Assessing the measles immunity profile is critical for developing effective nationwide or regionwide supplementary immunization activities (SIAs). This study aims to assess measles population immunity levels in China and investigate factors contributing to age-specific heterogeneities. Methods: We conducted a cross-sectional population-based serological study in southern China between June and October 2021. We determined the population mean antibody concentration and seroprevalence by age and over time, along with their associated determinants. Moreover, we estimated the contact-adjusted immunity levels by considering both age-specific immunity levels and population contact rates. Results: Among the 1015 study participants (aged 0-95 years), the overall seroprevalence was estimated at 80.9% (95% confidence interval [CI], 78.3-83.3). When adjusting for the age-specific contact rates, the contact-adjusted immunity was estimated at 66.8% (95% CI, 56.6-75.1). Individuals younger than age 30 years showed significantly lower antibody concentration and seroprevalence (mean log concentration: 5.9, seroprevalence: 73.6% [95% CI, 69.9-77.3]) compared to those older than age 50 years (mean log concentration: 6.8, seroprevalence: 96.8% [95% CI, 94.7-98.9]). In particular, individuals born after the last SIA (2010) showed a significantly faster waning of immunity. Conclusions: Our findings highlight that immunity levels in the general population remain below the 95% threshold, underscoring the need for continued monitoring of immunity dynamics, especially for individuals born in a near-elimination setting and without subsequent SIAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.